论文部分内容阅读
NIFEVIROC, a small molecular compound, is a proprietary drug candidate which is developed by TARGETDRUG and holds great promise in inhibiting HIV-1 replication in infected paitents.Preclinical studies suggested that NIFEVIROC is a specific CCR5 antagonist determined by multiple receptor functional assays.In addition, NIFEVIROC demonstrated potent inhibition activity against HIV-1 entry into the target cells by effectively blocking the human CCR5 receptors on the cell membrane.Furthermore, NIFEVIROC showed strong antiviral activity against wide variety of HIV strains, including those multi-drug resistant mutants.